Quisinostat, a highly potent second-generation selective HDAC inhibitor with orally activity, has demonstrated promising therapeutic effects against MM in rodent models and human samples tested in vitro [44–46]. The gene discussed is HDAC9; the disease is Miyoshi myopathy.